tetano
Editor, Senior Moderator
Diagnostics (Basel)
. 2020 Jul 31;10(8):E548.
doi: 10.3390/diagnostics10080548.
Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension
Jorge Nuche[SUP] 1 2 3 4 [/SUP], Teresa Segura de la Cal[SUP] 2 [/SUP], Carmen Jim?nez L?pez Guarch[SUP] 1 2 4 [/SUP], Francisco L?pez-Medrano[SUP] 4 5 [/SUP], Carmen P?rez-Olivares Delgado[SUP] 2 [/SUP], Fernando Arribas Ynsaurriaga[SUP] 1 2 4 [/SUP], Juan F Delgado[SUP] 1 2 4 [/SUP], Borja Ib??ez[SUP] 1 3 6 [/SUP], Eduardo Oliver[SUP] 1 3 [/SUP], Pilar Escribano Sub?as[SUP] 1 2 4 [/SUP]
Affiliations
Abstract
The Coronavirus Disease of 2019 (COVID-19) has supposed a global health emergency affecting millions of people, with particular severity in the elderly and patients with previous comorbidities, especially those with cardiovascular disease. Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) could represent an especially vulnerable population because of the high mortality rates reported for respiratory infections. However, the number of COVID-19 cases reported among PAH and CTEPH patients is surprisingly low. Furthermore, the clinical picture that has been described in these patients is far from the severity that experts would expect. Endothelial dysfunction is a common feature between patients with PAH/CTEPH and COVID-19, leading to ventilation/perfusion mismatch, vasoconstriction, thrombosis and inflammation. In this picture, the angiotensin-converting enzyme 2 plays an essential role, being directly involved in the pathophysiology of both clinical entities. Some of these common characteristics could explain the good adaptation of PAH and CTEPH patients to COVID-19, who could also have obtained a benefit from the disease's specific treatments (anticoagulant and pulmonary vasodilators), probably due to its protective effect on the endothelium. Additionally, these common features could also lead to PAH/CTEPH as a potential sequelae of COVID-19. Throughout this comprehensive review, we describe the similarities and differences between both conditions and the possible pathophysiological and therapeutic-based mechanisms leading to the low incidence and severity of COVID-19 reported in PAH/CTEPH patients to date. Nevertheless, international registries should look carefully into this population for better understanding and management.
Keywords: COVID-19; endothelial dysfunction; pulmonary circulation; pulmonary hypertension.
. 2020 Jul 31;10(8):E548.
doi: 10.3390/diagnostics10080548.
Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension
Jorge Nuche[SUP] 1 2 3 4 [/SUP], Teresa Segura de la Cal[SUP] 2 [/SUP], Carmen Jim?nez L?pez Guarch[SUP] 1 2 4 [/SUP], Francisco L?pez-Medrano[SUP] 4 5 [/SUP], Carmen P?rez-Olivares Delgado[SUP] 2 [/SUP], Fernando Arribas Ynsaurriaga[SUP] 1 2 4 [/SUP], Juan F Delgado[SUP] 1 2 4 [/SUP], Borja Ib??ez[SUP] 1 3 6 [/SUP], Eduardo Oliver[SUP] 1 3 [/SUP], Pilar Escribano Sub?as[SUP] 1 2 4 [/SUP]
Affiliations
- PMID: 32752129
- DOI: 10.3390/diagnostics10080548
Abstract
The Coronavirus Disease of 2019 (COVID-19) has supposed a global health emergency affecting millions of people, with particular severity in the elderly and patients with previous comorbidities, especially those with cardiovascular disease. Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) could represent an especially vulnerable population because of the high mortality rates reported for respiratory infections. However, the number of COVID-19 cases reported among PAH and CTEPH patients is surprisingly low. Furthermore, the clinical picture that has been described in these patients is far from the severity that experts would expect. Endothelial dysfunction is a common feature between patients with PAH/CTEPH and COVID-19, leading to ventilation/perfusion mismatch, vasoconstriction, thrombosis and inflammation. In this picture, the angiotensin-converting enzyme 2 plays an essential role, being directly involved in the pathophysiology of both clinical entities. Some of these common characteristics could explain the good adaptation of PAH and CTEPH patients to COVID-19, who could also have obtained a benefit from the disease's specific treatments (anticoagulant and pulmonary vasodilators), probably due to its protective effect on the endothelium. Additionally, these common features could also lead to PAH/CTEPH as a potential sequelae of COVID-19. Throughout this comprehensive review, we describe the similarities and differences between both conditions and the possible pathophysiological and therapeutic-based mechanisms leading to the low incidence and severity of COVID-19 reported in PAH/CTEPH patients to date. Nevertheless, international registries should look carefully into this population for better understanding and management.
Keywords: COVID-19; endothelial dysfunction; pulmonary circulation; pulmonary hypertension.